New combo therapy tested for Tough-to-Treat returning breast cancer
NCT ID NCT06849947
Summary
This study is for people with a specific type of advanced breast cancer (HR+, HER2-) that has spread and has come back after they finished a prior course of hormone-blocking pills. It will test if adding a drug called ribociclib to standard hormone therapy (fulvestrant) works better than other standard hormone therapy options chosen by a doctor. The main goal is to see which treatment can keep the cancer from growing for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.